Fig. 7: Impact of NO-CSF1Ri therapy in immune-competent murine models.
From: S-nitrosylation of CSF1 receptor increases the efficacy of CSF1R blockage against prostate cancer
A Percentage of M1 (CD86+) and M2 (CD206+ CD163+) macrophages in U937 cells used as a model for macrophage differentiation using specific M1 and M2 cocktails when treated in the presence/absence of GSNO + CSF1Ri combination. Data are represented as mean ± SEM. ***P < 0.001; **P < 0.01, *P < 0.05. ns = not significant. B Experimental plan. C Tumor volume, animal weight, and tumor weight were represented for n = 5 animals per treatment condition. D Representative immunofluorescent images for tumor sections for mice treated with vehicle and a combination of GSNO and CSF1R inhibitor (NO-CSF1Ri) and stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue), and Cysteine sulfinic acid (red) (n = 3). E GSNOR activity was measured at 340 nm for 10 minutes using tumor lysates treated with a vehicle and a combination of GSNO and CSF1R inhibitor (n = 3). F Percent nitrite concentration under different treatment conditions as estimated using the Griess test in tumor lysates (n = 3). G Immune-phenotyping done in tumor cells in untreated and NO-CSF1Ri mice (n = 5) for various markers: CD206, CD19, iNOS, CD11b, Ly6C, Ly6G, TCRB, CD4, CD8, CD44, and CD62L respectively. Data are Mean ± SEM. ***P < 0.001; **P < 0.01, *P < 0.05.
